10-Q: RenovoRx Reports Strong Q1 2026 Revenue Growth

RenovoRx announces significant revenue acceleration in Q1 2026, driven by increased commercial adoption of its RenovoCath device, while its TIGeR-PaC trial nears enrollment completion.

Summary

• RenovoRx reported first-quarter 2026 revenues of $563,000, a 136% increase quarter-over-quarter and over 50% of total 2025 revenue.
• The company expanded its active commercial cancer centers to 16 as of May 6, 2026, with 32 additional centers in evaluation, significantly expanding its near-term commercial pipeline.
• Enrollment for the Phase III TIGeR-PaC trial is nearing completion, with 106 out of 114 patients randomized as of May 14, 2026, and final data anticipated in mid to late 2027.
• The company ended the quarter with $12.4 million in cash and cash equivalents, which it believes is sufficient to fund operations for at least the next 12 months.
• Net loss for the quarter was $3.5 million, compared to $2.4 million in the same period last year, with an accumulated deficit of $64.9 million as of March 31, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by strong commercial execution and revenue growth, despite ongoing operational losses inherent in a clinical-stage company.

Positives

• Significant revenue growth of 136% quarter-over-quarter in Q1 2026, reaching $563,000.
• Expansion of active commercial cancer centers to 16, with a pipeline of 32 additional centers.
• TIGeR-PaC Phase III trial enrollment is 93% complete, nearing the target of 114 patients.
• Strong repeat ordering behavior from existing customers indicates physician satisfaction and clinical utility.
• Cash and cash equivalents of $12.4 million are expected to fund operations for at least the next 12 months.
• The cost of RenovoCath devices manufactured under the Medical Murray supply agreement ($1,200 per device) is significantly lower than previous manufacturing methods ($8,300 per device).

Negatives

• Net loss increased by 45% to $3.5 million in Q1 2026 from $2.4 million in Q1 2025.
• Accumulated deficit stands at $64.9 million as of March 31, 2026.
• The company expects to continue incurring significant losses until regulatory approval for IAG is obtained, which is not guaranteed.
• The company is not currently in compliance with Nasdaq's minimum bid price requirement ($1.00 per share).

Risks

• The commercial viability of IAG remains subject to clinical trials and regulatory approvals.
• Failure of the TIGeR-PaC study to achieve results conducive to progressing the study or receiving NDA approval would cause significant harm.
• The company may need to raise additional capital, and failure to do so could force delays or cessation of product development and commercial efforts.
• The company is not currently in compliance with Nasdaq's minimum bid price requirement, risking delisting.
• Product candidates may exhibit undesirable side effects, delaying or precluding development or approval.
• Competition from existing drugs and therapies could reduce or eliminate the commercial opportunity.
• The company's ability to protect its intellectual property effectively is crucial for maintaining its competitive advantage.

Future Outlook

RenovoRx expects to grow revenue from RenovoCath sales sequentially throughout 2026. The company anticipates increased research and development expenses as it advances clinical development of IAG and the next-generation RenovoCath device. Selling, general, and administrative expenses are also expected to increase due to continued commercialization efforts and hiring of sales and marketing personnel. The company believes its current cash and cash equivalents are sufficient to fund operations for at least the next 12 months, but acknowledges the potential need for future capital raises.

Management Comments

• The combination of record quarterly revenue, rapid active cancer center expansion, and strong repeat ordering behavior demonstrates accelerating commercial momentum and supports the long-term opportunity for RenovoCath as both a standalone device and a foundational platform for future drug-device combination therapies.
• We continue to view the TIGeR-PaC trial as an important long-term value driver, while emphasizing that our current commercial strategy is independent of the trials ultimate outcome and timeline.
• We expect that TIGeR-PaC trial sites will continue transitioning to commercial use following completion of enrollment, representing a meaningful potential driver of revenue growth in the second half of 2026.

Industry Context

StockSavvy.ai notes that RenovoRx's Q1 2026 results reflect a growing trend in the oncology sector towards targeted therapies and localized drug delivery, aiming to improve efficacy while reducing systemic toxicity. The company's dual strategy of commercializing its RenovoCath device as a standalone product and advancing its IAG drug-device combination therapy positions it within a competitive but high-potential market segment.

Comparison to Industry Standards

• The revenue growth of 136% quarter-over-quarter for RenovoCath sales is significantly higher than typical growth rates for early-stage commercial medical device companies, suggesting strong market adoption.
• The TIGeR-PaC trial's enrollment progress (93% complete) is on track with many late-stage clinical trials, though the final data readout in mid-to-late 2027 is a standard timeline for Phase III oncology studies.
• The company's cash burn rate and accumulated deficit are consistent with other clinical-stage biotechnology companies investing heavily in R&D and commercialization efforts.

Management Changes

Legal Proceedings

• The company was not subject to any material legal proceedings during the three months ended March 31, 2026, and no material legal proceedings are subsequently outstanding or pending.

Related Party Transactions

• Dr. Ramtin Agah, Chief Medical Officer and Chairman of the Board, has a consulting agreement with the company for services as Chief Medical Officer, overseeing clinical trials. His agreement was amended and restated in November 2025, and he was appointed Executive Chairman effective February 27, 2026.
• Consulting fees paid to Dr. Agah for the year ended December 31, 2025, were $337,000.
• Discretionary bonuses were approved for Dr. Agah: $96,000 for the period ended March 31, 2026, and $121,000 for the period ended December 31, 2025.

Stakeholder Impact

• Shareholders may experience dilution from future capital raises.
• The company's ability to continue as a going concern depends on successful future financing and commercialization efforts.
• Patients may benefit from improved targeted oncology therapies and the RenovoCath device.
• Employees' roles and compensation may be affected by the company's growth and financial performance.

Next Steps

• Complete enrollment for the TIGeR-PaC Phase III clinical trial by the end of June 2026.
• Transition TIGeR-PaC trial sites to commercial use in the second half of 2026.
• Target 36 active commercial cancer centers by year-end 2026.
• Continue advancing broader clinical programs, including investigator-initiated trials.
• File a 510(k) with the FDA for the next-generation RenovoCath device next year.

Key Dates

Recommendation

RenovoRx shows promising commercial traction with significant revenue growth and a strong pipeline of commercial centers. However, the company continues to incur substantial losses, faces Nasdaq delisting concerns, and its core drug-device therapy (IAG) is still in clinical trials with no guarantee of approval. While the commercialization of RenovoCath is a positive development, the overall risk profile warrants a 'hold' recommendation until further clinical and financial milestones are achieved.

Keywords

RenovoRx, 10-Q, RenovoCath, TAMP therapy, IAG, pancreatic cancer, clinical trial, revenue growth, FDA, Nasdaq